Hypoxia-activated prodrug enhances therapeutic effect of sunitinib in melanoma.

Liu, Shujing; Tetzlaff, Michael T; Wang, Tao; Chen, Xiang; Yang, Ruifeng; Kumar, Suresh M; Vultur, Adina; Li, Pengxiang; Martin, James S; Herlyn, Meenhard; Amaravadi, Ravi; Li, Bin; Xu, Xiaowei

Liu, Shujing; Tetzlaff, Michael T; Wang, Tao; Chen, Xiang; Yang, Ruifeng; Kumar, Suresh M; Vultur, Adina; Li, Pengxiang; Martin, James S; Herlyn, Meenhard; Amaravadi, Ravi; Li, Bin; Xu, Xiaowei.

Afiliação

Liu S; Department of Dermatology, Yueyang Hospital, Shanghai 200437, China.
Tetzlaff MT; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Wang T; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Chen X; Office of Biotechnology Products, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD 20993, USA.
Yang R; Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, China.
Kumar SM; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Vultur A; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Li P; The Wistar Institute, Philadelphia, PA 19104, USA.
Martin JS; Leonard Davis Institute of Health Economics, Philadelphia, PA 19104, USA.
Herlyn M; Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Amaravadi R; The Wistar Institute, Philadelphia, PA 19104, USA.
Li B; Department of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
Xu X; Department of Dermatology, Yueyang Hospital, Shanghai 200437, China.